# Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

> **NCT01090453** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 480 (actual)

## Conditions studied

- Tetanus
- Hepatitis B
- Haemophilus Influenzae Type b
- Poliomyelitis
- Acellular Pertussis
- Diphtheria
- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** GSK2202083A vaccine
- **BIOLOGICAL:** Prevenar 13®
- **BIOLOGICAL:** Infanrix hexa™
- **BIOLOGICAL:** Menjugate®
- **BIOLOGICAL:** Rotarix™

## Key facts

- **NCT ID:** NCT01090453
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-17
- **Primary completion:** 2011-10-11
- **Final completion:** 2011-10-11
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090453, "Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01090453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*